Precision Signals
Precision Signals
Podcast Description
Precision Signals is a podcast from the CEO Roundtable on Cancer about decoding biomedical progress: what’s real, what matters, and what’s next. We talk with scientists, regulators, investors, and builders operating across the messy interface of research, healthcare, and policy. Some are moving the system from within; others are reshaping it from the outside. All of them bring signal in a world crowded with noise.
Podcast Insights
Content Themes
The podcast covers critical topics related to biomedical research, healthcare systems, and regulatory frameworks. Episodes like 'The Mission is the Boss' focus on the challenges in clinical trials, discussing the journey of innovators like Dr. Michelle Longmire, while another episode, 'AI in Oncology: Hype, Evidence, and the Threshold of Clinical Trust', dives into the critical necessity of randomized trials for AI adoption in cancer care, illustrating the intricate balance between innovation and practical application.

Precision Signals is a podcast from the CEO Roundtable on Cancer about decoding biomedical progress: what’s real, what matters, and what’s next. We talk with scientists, regulators, investors, and builders operating across the messy interface of research, healthcare, and policy. Some are moving the system from within; others are reshaping it from the outside. All of them bring signal in a world crowded with noise.
In the late 1990s, much of oncology regarded cancer immunology as closer to mysticism than science. Jedd Wolchok, MD, PhD, was among the few who connected the early signals into a case that the immune system could control cancer.
On this episode of Precision Signals, Sean Khozin, MD, MPH, speaks with Dr. Wolchok, Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. Dr. Wolchok was instrumental in the clinical development of ipilimumab, the first approved immune checkpoint inhibitor, led the clinical development of combined CTLA-4 and PD-1 blockade, and led the work that defined the immune-related response criteria.
The conversation covers the mentors who shaped his career, the evidence that sustained the field through years of skepticism, why tumors can appear to grow before they respond, the search for better biomarkers, the role of AI in understanding tumor biology and measuring response, cell therapy for solid tumors, and his work bringing clinical trials to patients in Brooklyn and Queens.

Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.